Abivax S.A. Files 6-K for H1 2025 Financials

TL;DR

Abivax 6-K out: H1 2025 financials show capital & earnings details.

AI Summary

Abivax S.A. filed a 6-K report for the period ending June 30, 2025. The filing includes financial data for the first half of 2025 and the full year 2024, detailing aspects like issued capital, share premium, and retained earnings. Specific financial figures for these categories are presented for the periods ending December 31, 2023, and June 30, 2025.

Why It Matters

This filing provides investors with an update on Abivax's financial position as of mid-2025, offering insights into capital structure and retained earnings.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) providing an update on financial data, not announcing significant new events or risks.

Key Numbers

• 2025 Q2 — Reporting Period (Indicates the financial data covers the second quarter of 2025.)
• 12/31 — Fiscal Year End (Specifies the company's fiscal year concludes on December 31st.)

Key Players & Entities

• Abivax S.A. (company) — Filer of the report
• 20250630 (date) — End of reporting period
• 20250908 (date) — Filing date

FAQ

Key Financial Figures

• $150.0 million — aggregate gross sales proceeds of up to $150.0 million (the "ATM Program"). To date, we have
• $64.00 — ares in the form of ADSs, at a price of $64.00 per share (corresponding to 54.58 per o
• $140.0 — the Offering as follows: approximately $140.0 (119.4) million to $185.0 ( 157.8 ) mil
• $185.0 — approximately $140.0 (119.4) million to $185.0 ( 157.8 ) million to fund the clinical
• $30.0 — t of obefazimod for UC; approximately $30.0 (25.6) million to $65.0 ( 55.4 ) millio
• $65.0 — approximately $30.0 (25.6) million to $65.0 ( 55.4 ) million to fund the clinical d

Filing Documents

• abvx-20250630.htm (6-K) — 3688KB
• item991-pressreleaseh12025.htm (EX-99.1) — 49KB
• 0001956827-25-000031.txt ( ) — 17902KB
• abvx-20250630.xsd (EX-101.SCH) — 117KB
• abvx-20250630_cal.xml (EX-101.CAL) — 99KB
• abvx-20250630_def.xml (EX-101.DEF) — 478KB
• abvx-20250630_lab.xml (EX-101.LAB) — 804KB
• abvx-20250630_pre.xml (EX-101.PRE) — 675KB
• abvx-20250630_htm.xml (XML) — 4768KB

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly. Abivax SA (Registrant) Date: September 8, 2025 /s/ Marc de Garidel Chief Executive Officer 4 Exhibit 99.2 Unaudited Interim Condensed Consolidated Financial Statements TABLE OF CONTENTS Page INTRODUCTION ................................................................................................................. 1 RISK FACTORS ................................................................................................................... 3 OPERATING RESULTS ........................................................................................................ 4 INDEX TO THE UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL F-1 5 INTRODUCTION Unless otherwise indicated or the context otherwise requires, "Abivax," "the Company," "the Group," "we," "us" and "our" refer to Abivax SA and its consolidated subsidiary, taken as a whole. "Abivax" and the Abivax logo and other trademarks or service marks of Abivax SA appearing in this half-year report are the property of Abivax SA. Solely for convenience, the trademarks, service marks and trade names referred to in this half-year report are listed without the and symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their right thereto. All other trademarks, trade names and service marks appearing in this half-year report are the property of their respective owners. We do not intend to use or display other companies' trademarks and trade names to imply any relationship with, or endorsement or sponsorship of us by, any other companies. This half-year report includes our u naudited interim condensed consolidated fin

RISK FACTORS

RISK FACTORS The Company's business faces significant risks. You should carefully consider all of the information set forth in this document and in the Company's other filings with the SEC, including the risk factors which the Company faces and which are faced by the Company's industry described in "Item 3.D—Risk Factors" of the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024. Our risk factors have not changed materially from those described in our Annual Report on Form 20-F. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. 8 OPERATING RESULTS Overview We are a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Our lead drug candidate, obefazimod, is currently being evaluated in the following indications: Ulcerative colitis ("UC") : Phase 3 clinical trials for the treatment of adults with moderately to severely active UC are ongoing ("ABTECT"). On July 22, 2025, we announced the positive Phase 3 results of our ABTECT 8-week induction trials. Top-line results from the 44-week maintenance data read-out expected during the second quarter of 2026. Crohn's disease ("CD") : On October 3, 2024, we announced the first patient enrolled in our ENHANCE- CD Phase 2b clinical trial of obefazimod in patients with CD with the 12-week induction data read-out expected in second half of 2026. Combination therapy : In September 2024, we announced initial preclinical combination data of obefazimod combined with etrasimod in a mouse model of inflammatory bowel diseases (" IBD"). The results showed that treatment with the combination improved the response on body weight protection and Disease Activity Index and a synergistic and statistically significant reduction of several cytokines (TNFa, IL-17, IL-6, I

financial statements included in this half-year report, to be able to fund our forecasted cash flow requirements into

financial statements included in this half-year report, to be able to fund our forecasted cash flow requirements into the fourth quarter of 2027, allowing us to reach 12 months of expected cash runway post the planned NDA submission for UC, assuming positive results from its Phase 3 maintenance trial. Our forecasted cash flow requirements take into account our assumption of continued R&D expenditure related to the continuation of the Phase 3 clinical trials of obefazimod in UC, progression of the Phase 2b clinical trials for CD and the initial stages of the scale up of the commercial organization as we prepare for a potential launch of obefazimod in UC. Based on the above, management has concluded that the substantial doubt about our ability to continue as a going concern has been alleviated beyond 12 months from the date of issuance of the financial statements accompanying this half-year report, and the accompanying financial statements have been prepared on a going concern basis. 13 Capital Increases During the six-month period ending June 30, 2025, t here has been one capital increase relating to the vesting of 124,096 AGAs, resulting in the issuance of 124,096 ordinary shares with a par value of 0.01 per share . On July 28, 2025, we received gross proceeds of 637.5 million from the issuance of 11,679,400 ordinary shares in the form of ADSs, at a price of $64.00 per share (corresponding to 54.58 per ordinary share) . We intend to use the net proceeds from the Offering as follows: approximately $140.0 (119.4) million to $185.0 ( 157.8 ) million to fund the clinical development of obefazimod for UC; approximately $30.0 (25.6) million to $65.0 ( 55.4 ) million to fund the clinical development of obefazimod for CD; and the remainder for working capital and for other general corporate purposes, including preparation of commercialization, additional research and development and financing expenses. Research Tax Credits From our inception to Jun

View Full Filing

View this 6-K filing on SEC EDGAR